- $58.75m
- $37.87m
- $48.47m
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gossamer Bio - Board Approves Amendment And Restatement Of Bylaws Effective Sept 3, 2026 - SEC Filing
Gossamer Bio Inc expected to post a loss of 12 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- BioLife Solutions, Gossamer Bio, Intuit
Brief: Gossamer Bio, Inc. Announces Final Tender Results For Exchange Offer And Consent Solicitation With Respect To Existing Convertible Notes
Gossamer Bio Q1 net loss widens on higher R&D expenses
Brief: Gossamer Bio Launches Exchange Offer And Consent Solicitation Intended To Eliminate Over $120 Million Of Debt With Existing Noteholder Support
Brief: Gossamer Bio Q1 EPS USD -0.2
Gossamer Bio Q4 net loss widens
U.S. STOCKS ON THE MOVE-AbbVie, CrowdStrike, PayPal
U.S. STOCKS ON THE MOVE-Enhabit, Ethos Technologies, gold miners
Gossamer Bio falls after experimental lung condition drug fails in trial
NASDAQ RESUMED AT 08:35 AM
Gossamer Bio's experimental lung condition drug fails in late-stage trial (updated)
Gossamer Bio's experimental lung condition drug fails in late-stage trial
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:58 AM
Brief: Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)